WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015119570) PRL-3 AS A BIOMARKER FOR THE PROGNOSIS OF CANCER AND A TARGET FOR THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/119570    International Application No.:    PCT/SG2014/000052
Publication Date: 13.08.2015 International Filing Date: 07.02.2014
IPC:
G01N 33/53 (2006.01), C12Q 1/68 (2006.01), A61K 39/395 (2006.01), A61P 35/02 (2006.01), C07K 16/32 (2006.01)
Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis Singapore 138632 (SG)
Inventors: ZENG, Qi; (SG)
Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office Singapore 903031 (SG)
Priority Data:
Title (EN) PRL-3 AS A BIOMARKER FOR THE PROGNOSIS OF CANCER AND A TARGET FOR THERAPY
(FR) PRL-3 COMME BIOMARQUEUR POUR LE PRONOSTIC DE CANCER ET COMME CIBLE DE THÉRAPIE
Abstract: front page image
(EN)Previously, we have shown that a cancer associated-PRL-3 intracellular phosphatase is a potential therapeutic target for PRL-3 antibody therapy. PRL-3 has recently emerged as a potentially useful biomarker for cancer prognosis, particularly the prediction of cancer metastasis (Matsukawa et al, 2010; Ren et al, 12 2009). Here we demonstrate that PRL-3 can act as an independent prognostic marker for cancers.
(FR)Précédemment, nous avons démontré qu'une phosphatase intracellulaire PRL-3 associée au cancer est une cible thérapeutique potentielle pour la thérapie aux anticorps PRL-3. Le PRL-3 a récemment émergé comme biomarqueur potentiellement utile pour le pronostic du cancer, en particulier la prédiction de métastase du cancer (Matsukawa et al, 2010 ; Ren et al, 12 2009). Nous démontrons ici que le PRL-3 peut agir comme un marqueur de pronostic indépendant pour les cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)